N
JUNO

Nuveen’s Juno Therapeutics, Inc. JUNO Stock Holding History

Nuveen’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,477
Closed -$694K – 1184
2017
Q3 		$694K Sell
15,477
-4,650
-23% -$159K ﹤0.01% 848
2017
Q2 		$602K Buy
+20,127
New +$497K ﹤0.01% 892

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Nuveen's JUNO Position: Q4 2017 in Review

Nuveen sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 15,477 shares — an estimated $694K sold.

Nuveen first reported a position in JUNO in Q2 2017 and held it in 2 quarters. The position peaked at $694K in Q3 2017. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Nuveen reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nuveen sold 15,477 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $694K.
  • Nuveen first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Nuveen's Juno Therapeutics, Inc. position peaked at $694K in Q3 2017.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Nuveen's 13F filing for Q4 2017, filed 14 Feb 2018.